Artificial Intelligence

A fintech firm's new hire seems distant, but it signals a crucial shift in how capital flows into life-saving research and healthcare innovation.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

JCDecaux's new AI measures MTR audiences with precision, but can it win public trust by balancing data insights with total anonymity?

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

A new AI system deters birds to prevent avian flu. But its real innovation lies in data, transforming biosecurity from a costly chore into a profitable investment.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

California's Movandi is moving to Riyadh. A look at how sovereign incentives are building a new semiconductor hub and the wireless backbone for an AI future.

FDA greenlights the first precision therapy for BRCA2-mutated mCSPC, a highly aggressive prostate cancer, slashing progression risk by 54%.

Beyond the runway hype, AI is now a core driver of commerce. But does it level the playing field or just raise the stakes for everyone involved?

Beyond a simple date change for its $10M dividend, Dominari Holdings is signaling a major strategic shift, funded by investment gains and aimed at AI.

Clairvest's successful exit from F12.net yields a 35% IRR, showcasing a powerful growth strategy for private equity in Canada's booming MSP market.

As winter storms loom, a silent threat enters our homes. Learn the critical, life-saving steps to protect your family from carbon monoxide and fire.

As AI adoption surges, one firm's rigorous SOC 2 compliance offers a new blueprint for trust in an era of high-stakes data and complex cyber threats.

HCIactive's SmartBenefits.ai promises AI-powered clarity for your health plan, but a major data breach reveals the high-stakes risks of this new frontier.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.